A Phase II, single-arm, open-label clinical study enrolled 105 patients with PD-L1-positive recurrent or metastatic cervical cancer who had progressed after first-line or subsequent first-line chemotherapy. The gene discussed is CD274; the disease is cervical carcinoma.